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ABSTRACT 
Objectives: Nationwide Danish guidelines regarding rheumatoid arthritis (RA) patients 
initiating biological treatment(bDMARDs) are issued approximately annually. For bio-naïve 
patients treated with concomitant methotrexate, the mandatory drugs were: certolizumab 
pegol (year: 2013-2014, recommended compliance: 80%); abatacept(2014-2015, 80%); 
biosimilar infliximab(CT-P13) (2015-2016, 50%). We hypothesized that the guidelines could 
be perceived as a surrogate randomization tool where calendar time rather than patient-
specific factors defined choice of bDMARD. Objectives were to 1) assess compliance to 
guidelines (supporting the assumption of surrogate randomization); 2) compare 
effectiveness of certolizumab pegol, abatacept and CT-P13 in patients treated according to 
guidelines. 
Methods: Observational cohort study emulating a randomized trial (intention-to-treat). RA 
patients compliant to the guidelines were identified in DANBIO and information on prior 
comorbidities were obtained through linkage to national registries.  Outcomes were DAS28-
remission-rates (at 6/12-months) and one-year treatment retention, compared across 
treatments (comorbidity/confounder-adjusted multivariable logistic and Cox-regression 
analyses). 
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Results:  776 patients were included (certolizumab/abatacept/CT-P13: 336/215/225). 
Compliance to guidelines was high (70%/65%/59%).  Six and 12 months’ DAS28 remission 
rates were: 35%/33%/42% and 35%/31%/35%, respectively. Compared with certolizumab, 6 
and 12 months’ adjusted odds ratios(OR) for DAS28 remission were for abatacept 
OR=0.96(95%CI:0.63,1.47) and 0.74(0.47,1.15), for CT-P13 OR=1.38(0.91,2.09) and 
0.96(0.62,1.49), respectively. Adjusted hazard ratios(HR) for withdrawal (during 0-90 
days/91-365 days) were for abatacept HR=0.70(95% CI 0.39,1.27)/1.16(0.84,1.60) and for 
CT-P13 HR=0.58(0.33,1.10)/0.83(0.59,1.17), compared with certolizumab.  
Conclusion: The surrogate randomization procedure enabled head-to-head comparison of 
certolizumab pegol, abatacept and CT-P13. Although some differences in the estimated 
effectiveness were observed across drugs, confidence intervals were wide and statistical 
significance was not reached. 
 
INTRODUCTION 
Rheumatoid arthritis (RA) is a severe inflammatory joint disease associated with pain, 
disability and joint destruction. An increasing number of biological disease-modifying anti-
rheumatic drugs (bDMARDs) is now available. Randomized controlled trials (RCTs) are 
considered the gold standard for assessing drug effects. (1) In RCTs with intention-to-treat 
analyses (ITT), the different bDMARDs in combination with methotrexate (MTX) appear to 
have similar efficacy, (2-4) but only some of the RCTs have performed direct comparison of 
different bDMARDs.(5, 6) Observational studies in routine care are a valuable supplement to 
RCTs due to the inclusion of less restricted populations, longer follow-up time and lower 
costs. However, lack of randomization makes observational effect estimates vulnerable to 
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confounding, including confounding by indication.(7) Interestingly, it has been shown that a 
properly designed observational study may produce results very similar to that of RCTs, 
when observational data emulate a RCT.(8)  
DANBIO is a Danish nationwide registry of patients with inflammatory 
arthritis.(9) Patients are monitored prospectively in routine care with coverage >95% for 
bDMARD treated patients.(10) Through linkage to other national registries DANBIO data can 
be enriched with information on e.g. hospitalizations, comorbidities, and vital status.(11)  In 
Denmark, nationwide guidelines on mandatory choice of bDMARD are issued approximately 
annually based on a combination of expert opinion and costs. The guidelines include the 
expected proportion of patients treated according to the guideline (=compliance).(12) The 
guidelines are enforced by the financial incentive of the departments, since the cheapest 
drug is selected as first choice in the guideline among drugs considered to be equally 
effective and with comparable safety profile. Also, the treating physician must argue for any 
deviation from the guideline in each individual case. Between 2013 and 2016, certolizumab 
pegol (a tumor necrosis factor inhibitor, TNFi), abatacept (an inhibitor of co-stimulation of T-
cells) and CT-P13 (biosimilar infliximab) were successively the recommended bDMARDs in 
combination with MTX in biologics-naive RA patients with insufficient prior response to 
csDMARDs.  
We hypothesized that the guidelines could be perceived as a surrogate 
randomization tool(13, 14) and that choice of bDMARD would be determined by calendar 
period rather than by patient-specific factors, thus minimizing confounding by indication. 
This might provide a unique opportunity for emulating an RCT thus enabling the comparison 
of real-world effectiveness of three drugs that have never been compared directly in the 
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same RCT. The “ideal hypothetical trial” that this observational study attempted to emulate 
would be a pragmatic trial, where eligible patients were biologics-naïve patients with RA 
who were inadequate responders to MTX/csDMARD and who initiated their first bDMARD 
between 2013-2016. They would be randomized to either certolizumab pegol, abatacept or 
CT-P13, and the treatment effect and adherence would be compared after 6 and 12 
months.(15, 16) 
The aims of the current study were therefore two-fold: 1) to assess compliance 
to the guidelines to support the assumption of surrogate randomization and 2) to compare 
the effectiveness of treatment with certolizumab pegol, abatacept and CT-P13 given in 
combination with concomitant MTX in bDMARD naïve patients with RA in routine care. 
 
PATIENTS AND METHODS 
National treatment guidelines and compliance to them 
In Denmark, treatment with bDMARDs is tax paid, which facilitates equal access to 
expensive therapies. For drugs considered equally effective, a tender-process takes place 
approximately annually, after which it is mandatory to prescribe the cheapest drug as first 
bDMARD treatment. The expected compliance to the guideline is stated, i.e. the 
rheumatologists must prescribe the cheapest drug in e.g. 50% or 80% of the patients during 
the calendar period that the guideline covers.(17) Between 2013 and 2016, certolizumab 
pegol (Jan 1th 2013-June 30th, 2014), abatacept (July 1th 2014 – June 30th, 2015) and CT-P13 
(July 1th 2015-June 30th, 2016) were recommended as first line bDMARDs in biologic-naïve 
RA patients concomitantly treated with MTX, with expected compliance of 80%, 80% and 
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50%, respectively. For each of the three calendar periods, the proportion of all biologic-
naïve RA patients who started first bDMARD in combination with MTX in accordance with 
the national guidelines was calculated and compliance was assessed as: (numbers adherent 
to guidelines/numbers of all bio-naïve pts initiating bDMARD in combination with MTX) * 
100%. 
 
Study design 
For each of the three calendar periods, biologic-naïve patients were identified in DANBIO 
and included in this comparative effectiveness study, if they started bDMARD treatment 
(with concomitant MTX) in accordance with the guideline. Thereby we aimed at establishing 
a non-blinded observational cohort study with surrogate (calendar time) randomization.  
Patient characteristics and disease activity (baseline, 6 months, 12 months) 
were retrieved from DANBIO. Baseline (=index date) was defined as the start date of the 
bDMARD. Time windows were applied for baseline and follow-up visits as follows: Baseline 
was defined as the time window from 30 days before until 6 days after treatment start. For 
the 6-months visit, the time window was from 8 to 39 weeks and for the 12-months visit 
from week 40 to 72 weeks after treatment start. If more than one visit occurred within a 
given time window, the one closest to the given time point was selected for the analysis. 
By use of unique civil registration numbers, comorbidities prior to the index 
date in each patient were identified by linkage to the Danish National Registry of Patients 
(DNRP).(11) The DNPR has virtually complete data on in- and out-patient contacts (in-patient 
data since 1977 and out-patient since 1995). 
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Ethics 
According to Danish law, informed consent and ethical approval were not required for the 
present study. 
  
Clinical variables and outcomes 
The following baseline covariates were identified in DANBIO: age (years), gender 
(female/male), RA disease duration (years), anti-cyclic citrullinated peptide (anti-CCP) status 
(positive/negative), current smoking status (yes/no/missing), physician global score on a 
visual analogue scale (VAS) 0-100, patient pain VAS 0-100, fatigue VAS 0-100, patient global 
VAS 0-100, functional status (Health Assessment Questionnaire, HAQ (continuous, 0-3), C-
reactive protein (CRP, continuous) and glucocorticoid use at baseline (injections or oral) 
(yes/no). Similarly, at baseline and at the 6- and 12-month visits DAS28 (based on four 
variables and C-reactive protein; continuous),(18, 19) and clinical disease activity index (CDAI; 
continuous) were calculated. Remission criteria were: DAS28<2.6 and CDAI≤2.8. 
Study outcomes were: proportion of patients in DAS28 remission (ITT analysis) 
after 6 and 12 months, and one-year retention rates. Furthermore, odds for achieving 
DAS28 remission after 6 and 12 months, and one-year risk of withdrawal (hazard ratio, HR) 
were compared across treatments. Secondary outcomes were median DAS28 and 
proportion of patients in CDAI remission at 6 and 12 months.  
Comorbidities were identified in DNPR 10 years prior to baseline and the 
Charlson Comorbidity Index (CCI) score (0/ ≥ 1)  was calculated excluding category 7, 
connective tissue disease (Supplementary Table S1).(20)   
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 In the analysis of treatment retention, time on bDMARD was defined as 
number of days from baseline to the first of: stop date of the bDMARD, emigration, start of 
treatment with another bDMARD, death, or end of study period. The stop date was 
recorded in DANBIO by the treating physician as the date of first missed dose. Reasons for 
withdrawal (lack of effect/adverse events/cancer/pregnancy wish/treatment at another 
hospital/infection/loss to follow-up/death/surgery/project 
participation/remission/other/unavailable) were retrieved from DANBIO. End of study 
period was January 1st, 2018 to ensure 12 months of follow-up on patients in the third 
calendar period. 
Statistical analysis 
All analyses were conducted using SAS version 9.4. Descriptive statistics for continuous 
variables were summarized as medians and interquartile ranges (IQR), categorical variables 
were assessed as frequencies and percentages. 
Treatment responses at 6 and 12 months: For patient with missing DAS28 
remission status at 6 months, the following assumptions were made as part of an 
approximated ITT analysis: 1) patients who had withdrawn from treatment due to “lack of 
effect” were classified as not being in remission, 2) patients who had withdrawn due to 
“remission” were classified as being in remission, 3) patients still on treatment who had 
more than one swollen joint at 6 months were classified as not being in remission, 4) 
patients who still had missing outcome data were in the main analyses classified as not 
being in remission. Similar approaches were applied for DAS28 remission status at 12 
months and for CDAI remission. When calculating medians of DAS28, patients with missing 
DAS28 were excluded.  
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The odds of being in DAS28 remission at 6 months were estimated by logistic 
regression analyses adjusted for baseline confounders identified a priori as clinically 
relevant: a) age, gender, b) age, gender, DAS28, HAQ, smoking and CCI score (=fully 
adjusted). Certolizumab was the reference drug, because most patients were treated with 
this drug. In “best case/worst case” sensitivity analyses, the above-mentioned ITT analysis 
was expanded further to assess the impact of extreme endpoints: In patients who had 
missing outcome data for DAS28 remission (yes/no) at 6 months, logistic regression analyses 
were carried out where one drug at a time was assigned “best case” for all missing data and 
compared to the two other drugs assigned “worst case” for all missing data. In the “best 
case”, patients with missing data on DAS28 at 6 months were categorized as being in 
remission. In the “worst case” they were categorized as not being in remission (i.e. non-
responder imputation). Similar analyses were applied for DAS28 remission at 12 months. 
One-year treatment retention was investigated with multivariable Cox 
regression analyses adjusted for the above-mentioned confounders. The proportional 
hazard assumption was not met for the initial model but was fulfilled when analyses were 
done with separate effects for the time-intervals 0-90 days and 91-365 days.  
To mimic common inclusion and exclusion criteria in RCTs, further sensitivity 
analyses were done in which we excluded patients with severe comorbidities (myocardial 
infarction, cerebrovascular disease, dementia, hemiplegia, moderate to severe renal 
disease, diabetes with end organ damage, any tumor, leukemia, lymphoma, moderate to 
severe liver disease, metastatic solid tumor and AIDS) and only included patients with a 
baseline DAS28 > 3.2 who were seropositive for rheumatoid factor or anti-CCP. In these 
analyses, no adjustment for baseline comorbidities was done. 
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RESULTS 
Compliance to the national guidelines  
Table 1 shows the pattern of bDMARD prescriptions in the three calendar periods. The 
national guidelines were followed in 776 RA patients initiating certolizumab pegol (336 
patients), abatacept (215 patients) or CT-P13 (225 patients) (Table 1). Compliance regarding 
choice of drug in each calendar-period was 70%, 65% and 59%, respectively.  
 
Baseline characteristics of the patients included in the comparative effectiveness study 
Patients had similar DAS28, CDAI, CRP and patient reported outcomes (HAQ, VAS fatigue 
and pain) across treatments (Table 2). Patients treated with CT-P13 were slightly older and 
abatacept treated patients had fewer comorbidities and fewer were smokers (Table 2).  
 
Visits during follow-up 
The number of visits registered in DANBIO during the first year of treatment was similar for 
all three drugs (median = 3 visits). Furthermore, the median number of days until the 6- and 
12-months visits were similar for the three drugs (6 months: 186-199 days, 12 months: 385-
404 days).  
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Treatment responses at 6 and 12 months and one-year retention rates 
At 6 months, DAS28 remission had been achieved in 35% of certolizumab pegol, 33% of 
abatacept, and 42% of CT-P13 treated patients. At 12 months, it was 35%, 31% and 35%, 
respectively (ITT analyses) (Table 3). Results for CDAI showed similar patterns 
(Supplementary table S2). One-year crude retention rates were 60% for certolizumab pegol, 
57% for abatacept, and 69% for CT-P13. With certolizumab pegol as the reference drug, the 
estimated age- and gender adjusted OR for achieving DAS28 remission at 6 months was 
OR=0.95 (95% CI:0.65 to 1.39) for abatacept and OR=1.38, (0.95 to 1.99) for CT-P13. After 12 
months the corresponding results were OR= 0.84 (0.56 to 1.24) and OR=1.04 (0.70 to 1.54), 
respectively. Similar estimates were found in confounder-adjusted analyses (Figure 1). For 
all analyses the CIs included 1. ”Worst case” and “best case“ imputations changed the 
estimates so whichever drug that was assigned “best case” was superior to the two other 
drugs (assigned “worst case”, Supplementary table S3).  
 
Comparison of retention rates 
The estimated risk of withdrawal for abatacept was 30% lower (HR:0.70 (95% CI: 0.39 to 
1.27), fully adjusted model) than certolizumab pegol during the first 90 days of treatment. 
However, from 91 to 365 days the risk was 16% higher (HR:1.16 (0.84 to 1.60)), (Table 4). 
For CT-P13, the risk was 42% lower (HR:0.58 (0.33 to 1.10)) during the first 90 days and 17% 
lower from 91 to 365 days (HR:0.83 (0.59 to 1.17). All CIs included 1 (Table 4). After 6 
months’ follow-up, median DAS28 was 2.9 (IQR: 2.0-3.9) for certolizumab pegol, 3.0 (2.0-
3.9) for abatacept and 2.6 (2.0-3.8) for CT-P13 in patients still on treatment. Similarly, after 
12 months DAS28 was 2.2 (1.7-3.0) for certolizumab pegol, 2.4 (1.8-3.3) for abatacept and 
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2.5 (1.7-3.5) for CT-P13. Reasons for discontinuation (lack of effect, adverse events) are 
registered routinely in DANBIO. The main reason for withdrawal was lack of effect (36-60%) 
followed by adverse events (15-42%), while other reasons were given in less than 10% of 
cases. 
 
Sensitivity analyses restricted to patients fulfilling strict RCT in- and exclusion criteria 
Adherence to guidelines, baseline characteristics, treatment responses and retention rates 
were similar in the analyses that excluded patients with severe comorbidities and included 
only seropositive patients with a DAS28 >3.2. In the restricted cohort, the baseline 
characteristics, treatment responses and retention rates were largely similar across the 
three drugs, and the CI were wide (Supplementary table S4-S8). 
 
DISCUSSION 
In this paper we present how data from an observational cohort study of more than 700 bio-
naïve patients with RA who initiated treatment with bDMARD according to national 
guidelines during the years 2013 to 2016 could emulate an RCT study, which allowed a 
head-to-head comparison of certolizumab pegol, abatacept and CT-P13. Compliance to the 
guidelines was high. Although some differences in the estimated remission and retention 
rates were observed between the drugs, confidence intervals were wide and statistical 
significance was not reached.  
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RCTs are considered the gold standard for assessing the efficacy of bDMARDs. 
RCTs comparing the active drug with placebo or with another bDMARD have reported 
comparable treatment effects across the bDMARDs within each study.(5, 6, 21-23) However, 
inclusion criteria and definition of treatment responses have varied between RCT studies, 
which makes comparisons across studies difficult. Studies with indirect comparison of 
bDMARDs have reported equal effectiveness but with wide CIs and heterogeneity between 
studies.(24, 25) Observational cohort studies may be a valuable alternative when RCTs are 
considered too expensive or impossible to conduct.(26) Furthermore, it is of interest to study 
effectiveness in patients treated in routine care, as most of these patients would not have 
been eligible in an RCT.(27) Thus, in the present study the included patients represented a 
non-selected, nationwide cohort that started one of three bDMARDs within a limited time 
period, which enabled us to compare the three drugs directly. Historically, it has been 
claimed that the effect size is often higher in observational studies than in RCTs.(26) 
However, several recent studies comparing RCTs and observational studies could not 
confirm this.(1, 26, 28) Our study supports that a properly designed cohort study seems to 
produce results comparable to that of RCTs.  
We took several methodological steps to emulate an RCT. Firstly, we took 
advantage of the national guidelines, which resulted in a surrogate randomization 
procedure in which the choice of bDMARD was defined by the calendar time, thereby 
reducing confounding by indication. Compared to the calendar periods prior to and after 
each of the three drugs being first choice, a steep decline in number of patients treated with 
the three drugs was observed, demonstrating that compliance to the guidelines was high. 
Furthermore, similar baseline characteristics in the three cohorts indicated a successful 
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“randomization”.  Secondly, to assess the impact of missing follow-up data, we analyzed 
data by an ITT-methodology, and also conducted best/worst case analyses. Thirdly, linkage 
of DANBIO to other national registries (e.g. the DNPR) allowed us to adjust for a wide range 
of potential confounders, including comorbidities. We did this in two ways: by statistical 
modelling and by restriction of the cohort by applying some common exclusion criteria in 
RCTs (i.e. excluding patients with severe comorbidities, low disease activity or seronegative 
status).(29) Overall, the results of the various sensitivity analyses were largely similar, thus 
confirming the robustness of results.  
We took advantage of the fact that the treatment assignment was largely 
driven by the guidelines. Thus, confounding control started at the time of study design and 
not at the time of adjusted analyses.(14) As a result, patient characteristics at baseline were 
very similar across calendar years. Some patients did not adhere to the guidelines. We have 
previously investigated differences between those who adhered to guidelines and those 
who did not.(30) Patients adherent to the guidelines had higher DAS28 and patient global 
score, indicating that some selection of patients took place, which is similar to what is 
observed in the recruitment of patients for an RCT.(31) Shortly after CT-P13 was marketed in 
Denmark, the guidelines were revised and CT-P13 became the first choice (expected 
compliance 50%) whereas certolizumab became the second choice (with an expected 
compliance of 30%). We decided not to include the latter cohort in our emulated RCT since 
patient numbers were low and certolizumab at this point in time was only the second 
choice. 
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This study has strengths and limitations. High quality clinical prospective data from a 
nationwide rheumatologic registry, DANBIO, was enriched with data from a virtually 
complete national registry. Although we used ITT and best/worst case imputation to handle 
missing data, missingness still occurred. This is an inherent challenge of observational 
studies due to loss of follow-up and incomplete registrations. Some channeling cannot be 
ruled out. In contrast to what is the case in an RCT, the physician had other potential 
treatment alternatives. Since compliance to the guideline was not expected to be 100%, it 
was possible e.g. to prescribe rituximab rather than the recommended first choice to 
patients with a prior cancer. We found that CT-P13 patients were slightly older. 
Subcutaneously administered bDMARDs (i.e. abatacept and certolizumab pegol) may be 
preferred by younger patients associated with the labor market, because these treatments 
are less time consuming and require fewer hospital visits compared to intravenous 
treatments (i.e. CTP-13). A study from the Swedish Rheumatology Quality register (SRQ) 
showed that patients with poor health-status were channeled to non-TNFI bDMARDs, which 
made the non-TNFi bDMARDs appear more harmful compared to TNFi.(32) This may, at least 
in part, explain the slightly lower estimates of treatment responses found for abatacept (a 
non-TNFi bDMARD) in most of our analyses. 
In conclusion, in this observational study of more than 700 patients with RA treated 
according to the national Danish guidelines, we showed how a surrogate randomization 
procedure (calendar year), enabled direct comparison of the effectiveness of certolizumab 
pegol, abatacept and CT-P13. Although some differences in the estimated remission and 
retention rates across the three drugs were observed, the confidence intervals were wide, 
and no statistically significant differences were found.  
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Table 1 Prescription patterns of first bDMARD given in combination with MTX in the three 
calendar periods 
 
 Numbers (%) of RA patients who started bDMARD in combination with MTX 
 Jan 2013- June 2014 July 2014-June 2015 July 2015- June 2016 
Abatacept 6 (1%) 215 (65%) 23 (6%) 
Adalimumab 29 (6%) 20 (6%) 12 (3%) 
Certolizumab pegol 336 (70%) 31 (9%) 62 (16%) 
Etanercept (originator) 46 (10%) 8 (3%) 1 (0.5%) 
Etanercept (biosimilar, SB4) NA NA 14 (4%) 
Golimumab 10 (2%) 3 (1%) 0 
Infliximab (originator) 12 (3%) 4 (1%) 1 (0.5%) 
Infliximab (biosimilar, CT-P13) NA 7 (2%) 225 (59%) 
Rituximab 22 (5%) 14 (4%) 15 (4%) 
Tocilizumab 12 (3%) 27 (8%) 26 (7%) 
Total 474 (100%) 329 (100%) 379 (100%) 
 
Bold: first choice according to national guidelines. NA: Not applicable (i.e. the treatment not available in calendar period) 
 
Table 2 Baseline characteristics of RA patients following the Danish national guidelines 
during one of the three calendar periods and included in the comparative effectiveness 
study 
 
 
Certolizumab pegol 
N=336 
 Abatacept 
N=215 
 CT-P13 
N=225 
Calendar periods Jan 2013 – June 2014  July 2014-June 2015  July 2015-June 2016 
Expected guideline compliance (%) 80%  80%  50% 
Actual guideline compliance (%) 70%  65%  59% 
Baseline characteristics N   N   N  
Age, years 336 57 (48-65)  215 57 (48-65)  225 59 (50-66) 
Female, n (%) 336 240 (71%)  215 155 (72%)  225 153 (68%) 
Anti-CCP positive, n (%) 248 184 (74%)  168 129 (77%)  174 123 (71%) 
Disease duration, years 318 3 (1-10)  207 3 (1-9)  212 4 (2-10) 
Smoking current, n (%) 279 55 (20%)  191 21 (11%)  204 36 (18%) 
Glucocorticoids, n (%) 336 148 (44%)  215 118 (55%)  225 123 (55%) 
Physician global, mm  309 31 (18-46)  194 26 (17-41)  211 26 (16-42) 
Pain VAS, mm  320 58 (38-75)  197 63 (44-75)  214 61 (34-75) 
Fatigue VAS, mm 320 69 (44-82)  195 69 (40-84)  214 64 (40-82) 
DAS28 312 4.6 (3.8-5.3)  193 4.5 (3.9-5.3)  206 4.5 (3.7-5.3) 
CDAI 307 20 (14-28)  191 19 (13-26)  205 19 (13-26) 
HAQ  318 1.1 (0.6-1.8)  194 1.0 (0.6-1.6)  211 1.0 (0.6-1.6) 
Patient global VAS, mm 324 70 (49-84)  197 73 (51-84)  214 68 (48-85) 
CRP, mg/L 319 8 (3-18)  197 9 (3-20)  214 9 (4-20) 
CCI Score ≥ 1, n (%) 334 72 (22%)  213 35 (16%)  222 53 (24%) 
 
Variables are medians (IQR) unless otherwise stated. Abbreviations: CCI: Charlson Comorbidity Index, CRP: C-reactive protein, DAS28: 
Disease activity score in 28 joints; HAQ health assessment questionnaire; n: number of persons on which estimates are based; VAS: visual 
analogue scale 
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Table 3 DAS28 remission rates at 6 and 12 months stratified by treatment, ITT analyses 
 
 Certolizumab pegol Abatacept CT-P13 
Number of patients 336 215 225 
DAS28 remission, 6 months, n* (%) 116 (35%) 72 (33%) 94 (42%) 
DAS28 remission, 12 months, n* (%) 118 (35%) 67 (31%) 78 (35%) 
 
 *Missing data on DAS28 remission: 6 months: certolizumab pegol: 40 patients, abatacept: 25, CT-P13:29, 12 months: certolizumab pegol: 
74, abatacept: 51, CT-P13: 58.  
Abbreviations: DAS28: disease activity score in 28 joints, ITT: intention to treat. 
 
 
Table 4 Withdrawal during the first year of treatment. Results of adjusted Cox regression 
analyses  
 
 N HR (95% CI) 
  Certolizumab pegol Abatacept CT-P13 
0-90 days  
Adjusted for age and 
gender 
776 1.0 (ref) 0.78  (0.45 to 1.36) 0.63  (0.35 to 1.13) 
Fully adjusted*  720 1.0 (ref)  0.70  (0.39 to 1.27) 0.58  (0.33 to 1.10) 
91-365 days  
Adjusted for age and 
gender 
702 1.0 (ref) 1.15  (0.85 to 1.56) 0.74  (0.53 to 1.04) 
Fully adjusted*  652 1.0 (ref) 1.16  (0.84 to 1.60) 0.83  (0.59 to 1.17) 
 
*age, gender, DAS28, HAQ, smoking, CCI  
Abbreviations: CCI: Charlson Comorbidity Index: CI: confidence intervals, DAS28: Disease Activity Score of 28 joints, HAQ: Health 
assessment questionnaire, HR; hazard ratio 
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Legends to figures 
Figure 1 Adjusted odds ratios (OR) for achieving DAS28 remission at 6 and 12 months. 
Results of logistic regression analyses  
 
 
 
